Time to treatment with bridging intravenous alteplase before endovascular treatment:subanalysis of the randomized controlled SWIFT-DIRECT trial

Thomas R. Meinel(University of Bern), Johannes Kaesmacher(University of Bern), Lukas Buetikofer(University of Bern), Daniel Strbian(University of Helsinki), Omer Eker(Hospices Civils de Lyon), Christophe Cognard(Centre Hospitalier Universitaire de Toulouse), Pasquale Mordasini(University of Bern), Sandro Deppeler(University of Bern), Vítor Mendes Pereira(University Health Network), Jean François Albucher(Centre Hospitalier Universitaire de Toulouse), Jean Darcourt(Hospices Civils de Lyon), Romain Bourcier(Centre Hospitalier Universitaire de Nantes), B. Guillon(Centre Hospitalier Universitaire de Nantes), Chrysanthi Papagiannaki(Centre Hospitalier Universitaire de Rouen), Guillaume Costentin(Centre Hospitalier Universitaire de Rouen), Gerli Sibolt(University of Helsinki), Silja Räty(University of Helsinki), Benjamin Gory(Inserm), Sébastien Richard(Inserm), Jan Liman(Nuremberg Hospital), Marielle Ernst(Universitätsmedizin Göttingen), Marion Boulanger(Inserm), Charlotte Barbier(Inserm), Laura Mechtouff(Hospices Civils de Lyon), Liqun Zhang(St George’s University Hospitals NHS Foundation Trust), Gaultier Marnat(Université de Bordeaux), Igor Sibon(Université de Bordeaux), Omid Nikoubashman(RWTH Aachen University), Arno Reich(RWTH Aachen University), Arturo Consoli(Hôpital Foch), David Weisenburger(Hôpital Foch), Manuel Requena, Álvaro García‐Tornel, Suzana Saleme(Centre Hospitalier Universitaire de Limoges), Solène Moulin(Centre Hospitalier Universitaire de Reims), Paolo Pagano(Centre Hospitalier Universitaire de Reims), Guillaume Saliou(University Hospital of Lausanne), Emmanuel Carrera(Hôpital Beau-Séjour), Kévin Janot(Université de Tours), Martí Boix(Hospital Universitari Germans Trias i Pujol), Raoul Pop(Université de Strasbourg), Lucie Della Schiava(Centre Hospitalier Universitaire de Reims), Andreas R. Luft(University Hospital of Zurich), Michel Piotin(Fondation de Rothschild), Jean‐Christophe Gentric(Centre Hospitalier Régional Universitaire de Brest), Aleksandra Pikula(University Health Network), Waltraud Pfeilschifter(Goethe University Frankfurt), Marcel Arnold(University of Bern), Adnan H. Siddiqui(University at Buffalo, State University of New York), Michael T. Froehler(Vanderbilt University Medical Center), Anthony J. Furlan(Case Western Reserve University), René Chapot(Alfried Krupp Hospital), Martin Wiesmann(RWTH Aachen University), Paolo Machi(Hôpital Beau-Séjour), Hans‐Christoph Diener(Institut für Medizinische Informatik, Biometrie und Epidemiologie), Zsolt Kulcsár(University Hospital of Zurich), Leo H. Bonati(University Hospital of Basel), Claudio L. Bassetti(University of Bern), Simon Escalard(Fondation de Rothschild), David S. Liebeskind(University of California, Los Angeles), Jeffrey L. Saver(University of California, Los Angeles), Urs Fischer(University of Bern), Jan Gralla(University of Bern)
Journal of NeuroInterventional Surgery
July 28, 2022
Cited by 12Open Access
Full Text

Abstract

BACKGROUND: We hypothesized that treatment delays might be an effect modifier regarding risks and benefits of intravenous thrombolysis (IVT) before mechanical thrombectomy (MT). METHODS: We used the dataset of the SWIFT-DIRECT trial, which randomized 408 patients to IVT+MT or MT alone. Potential interactions between assignment to IVT+MT and expected time from onset-to-needle (OTN) as well as expected time from door-to-needle (DTN) were included in regression models. The primary outcome was functional independence (modified Rankin Scale (mRS) 0-2) at 3 months. Secondary outcomes included mRS shift, mortality, recanalization rates, and (symptomatic) intracranial hemorrhage at 24 hours. RESULTS: We included 408 patients (IVT+MT 207, MT 201, median age 72 years (IQR 64-81), 209 (51.2%) female). The expected median OTN and DTN were 142 min and 54 min in the IVT+MT group and 129 min and 51 min in the MT alone group. Overall, there was no significant interaction between OTN and bridging IVT assignment regarding either the functional (adjusted OR (aOR) 0.76, 95% CI 0.45 to 1.30) and safety outcomes or the recanalization rates. Analysis of in-hospital delays showed no significant interaction between DTN and bridging IVT assignment regarding the dichotomized functional outcome (aOR 0.48, 95% CI 0.14 to 1.62), but the shift and mortality analyses suggested a greater benefit of IVT when in-hospital delays were short. CONCLUSIONS: We found no evidence that the effect of bridging IVT on functional independence is modified by overall or in-hospital treatment delays. Considering its low power, this subgroup analysis could have missed a clinically important effect, and exploratory analysis of secondary clinical outcomes indicated a potentially favorable effect of IVT with shorter in-hospital delays. Heterogeneity of the IVT effect size before MT should be further analyzed in individual patient meta-analysis of comparable trials. TRIAL REGISTRATION NUMBER: URL: https://www. CLINICALTRIALS: gov ; Unique identifier: NCT03192332.


Related Papers

No related papers found

Powered by citation graph analysis